Medazepam

from Wikipedia, the free encyclopedia
Structural formula
Structure of medazepam
General
Non-proprietary name Medazepam
other names

7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine ( IUPAC )

Molecular formula C 16 H 15 CIN 2
External identifiers / databases
CAS number
  • 2898-12-6
  • 2898-11-5 (hydrochloride)
EC number 220-783-4
ECHA InfoCard 100,018,895
PubChem 4041
ChemSpider 3901
Wikidata Q572796
Drug information
ATC code

N05 BA03

Drug class
properties
Molar mass 270.8 g · mol -1
Physical state

firmly

Melting point

101-104 ° C

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling
no classification available
Toxicological data
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Medazepam is a drug from the group of benzodiazepines , and has amnestic , anxiolytic , anticonvulsant , hypnotic , sedative and muscle relaxing potential. It is used in medicine as an anxiolytic and as a daily tranquilizer for the symptomatic treatment of acute and chronic states of tension, excitement and anxiety .

Medazepam was patented by Hoffmann-La Roche in 1963 and launched on the market in 1969 under the finished drug name Nobrium .

Pharmacokinetics

After oral administration of Medazepam, maximum plasma concentrations are reached within one to two hours. The biological half-life is around two hours, that of its active metabolites desmethylmedazepam , desmethyldiazepam , diazepam and oxazepam up to 80 hours. The bioavailability of medazepam is 49 to 76% and the equivalent dose to 10 mg diazepam is 20 mg.

Side effects

Common side effects are drowsiness, dizziness, headache, drowsiness, and confusion. In rare cases, a paradoxical (opposing) effect with excitement (fear, aggressiveness, agitated state of confusion) can occur, which must never be answered by increasing the dose. Like all drugs from the benzodiazepine class, Medazepam has a high potential for dependence and abuse.

Trade names

Monopreparations

Nobrium (D, excluding trade), Rudotel (D, SK, HU, PL, RU), Ansilan (CZ, BA, MK), Resmit (JP)

Combination preparations

Debrum ( Medazepam & Trimebutine ) (IT), Nobritol ( Medazepam & Amitriptyline ) (SP), Tranko-Buskas ( Medazepam & Butylscopolamine ) (TR)

Individual evidence

  1. ↑ Joachim Ermer, John H. McB. Miller (Ed.): Method Validation in Pharmaceutical Analysis: A Guide to Best Practice . Validation of Pharmacopoeial Methods. WILEY-VCH, 2005, ISBN 978-3-527-31255-9 ( limited preview in the Google book search).
  2. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
  3. ↑ a b Entry on Medazepam. In: Römpp Online . Georg Thieme Verlag, accessed on June 29, 2019.
  4. ↑ a b Rudotel® specialist information. (PDF) (No longer available online.) In: teva.de. TEVA, formerly in the original ; accessed on March 26, 2019 .  ( Page no longer available , search in web archives )  Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice.@1@ 2Template: Dead Link / www.teva.de  
  5. ↑ Peter Riederer, Gerd Laux (Ed.): Neuro-Psychopharmaka: A Therapy Manual Volume 1 . Sales data of synthetic psychotropic drugs on the German market. Springer, 1992, ISBN 978-3-7091-7377-0 ( limited preview in Google book search).
  6. ^ DM Hailey, ES Baird: Plasma concentrations of medazepam and its metabolites after oral administration. . In: British Journal of Anesthesia . 51, No. 6, 1979, pp. 493-496. doi : 10.1093 / bja / 51.6.493 . PMID 37864 .
  7. ↑ R Jochensem, DD Breimer: Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles. . In: Current Medical Research and Opinion . 8, No. 4, 1984, pp. 60-79. doi : 10.1185 / 03007998409109545 . PMID 6144464 .
  8. ↑ Frank Schneider (Ed.): Clinic Manual Psychiatry, Psychosomatics and Psychotherapy . Chapter 10, Table 10.3. Springer, 2016, ISBN 978-3-642-54570-2 ( limited preview in Google book search).